The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.


All material subject to strictly enforced copyright laws. © 2022 Euromoney, a part of the Euromoney Institutional Investor PLC.
CAPITAL MARKETS

Deals of the year 2009: High grade –Swiss pharma Roche provides cure for quality concerns

February 07, 2010
Share

Swiss pharma's €12.66 billion bond perfect medicine in ultra-cautious market.

Global Awards
High grade High-yield
Equity M&A
Structured credit Restructuring
Regional Awards
Asia Latin America
CEE Middle East
Roche Eurobond and sterling issue: total €12.66 billion equivalent
4-year 6-year 7-year 12-year
€5.25 bln £1.25 bln €2.75 bln €1.75 bln
Issuer: Roche
Amount: €12.66 billion
Arrangers: Barclays Capital, BNP Paribas, Deutsche Bank, Santander
 

Take yourself back to the beginning of 2009. A dark cloud hung over the financial markets, the banking system had just been bailed out, yet systemic risk still lingered. The effects of massive central bank stimulus and government-backed bank bond guarantees had yet to kick fully into the sector. Loan markets remained crippled.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.

SUBSCRIBE ONLINE TODAY

Unlimited access to Euromoney.com and Asiamoney.com

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually

Subscribe today

FREE 7 DAY TRIAL

Unlimited access to Euromoney.com and Asiamoney.com, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors

Start free trial

LOGIN NOW

Already a user?

Login now

Tags

CAPITAL MARKETS Asia PacificCapital MarketsEmerging Europe
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree